What is Oncorus?
Oncorus is a clinical-stage biotechnology firm dedicated to transforming cancer treatment through next-generation viral immunotherapies. By leveraging its HSV Platform, the company develops candidates like ONCR-177, which are engineered for direct intratumoral administration to maximize local therapeutic impact while minimizing systemic toxicity. Furthermore, the company is pioneering a selectively self-amplifying vRNA Immunotherapy Platform, which integrates RNA and oncolytic virus modalities. This innovative approach aims to address significant unmet needs in oncology, with lead candidates currently undergoing IND-enabling studies to validate their potential as potent, systemic cancer therapies.
How much funding has Oncorus raised?
Oncorus has raised a total of $243.5M across 4 funding rounds:
Series A
$57M
Series B
$79.5M
Stock Offering
$87M
Debt
$20M
Series A (2016): $57M with participation from Long March Investment Fund, Excelyrate Capital, SunStates Fund, MPM Capital, Celgene, Inc, Arkin Bio Ventures, and Deerfield Management
Series B (2019): $79.5M led by Shinhan Investment-Private Equity, Sphera Funds, QUAD Investment Management, Perceptive Advisors, SV Investment Corp, IMM Investment, UTC Investment, Surveyor Capital, and Cowen Healthcare Investments
Stock Issuance/Offering (2020): $87M, investors not publicly disclosed
Debt (2022): $20M featuring K2 HealthVentures
Key Investors in Oncorus
K2 HealthVentures
An alternative investment firm providing flexible, long-term financing solutions to innovative private and public companies within the life sciences and healthcare sectors.
Perceptive Advisors
A New York-based investment firm managing significant assets with a dedicated focus on funding innovative healthcare and life sciences technologies.
Cowen Healthcare Investments
An independent financial services firm providing comprehensive investment banking, research, and management services to the healthcare industry.
What's next for Oncorus?
With the recent infusion of capital, Oncorus is well-positioned to accelerate its clinical roadmap. The strategic focus remains on advancing its lead HSV and vRNA programs through rigorous clinical trials and regulatory milestones. By maintaining a robust balance sheet, the company can effectively navigate the complexities of drug development, from IND-enabling studies to potential human efficacy trials. The firm's ability to attract diverse institutional backing—ranging from specialized life sciences venture firms to flexible debt providers—suggests a sustainable growth trajectory aimed at delivering high-impact, transformative outcomes for patients battling complex malignancies.
See full Oncorus company page
